These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 8614567

  • 21. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y, Yoshimura R, Nakai K, Itakura T.
    Brain Res; 2002 Aug 30; 947(2):271-83. PubMed ID: 12176170
    [Abstract] [Full Text] [Related]

  • 22. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D, Samantaray S, Mohanakumar KP.
    Synapse; 2003 Oct 30; 50(1):7-13. PubMed ID: 12872288
    [Abstract] [Full Text] [Related]

  • 23. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
    Naoi M, Maruyama W, Inaba-Hasegawa K.
    Expert Rev Neurother; 2013 Jun 30; 13(6):671-84. PubMed ID: 23739004
    [Abstract] [Full Text] [Related]

  • 24. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
    Zhao Q, Cai D, Bai Y.
    Int J Mol Med; 2013 Oct 30; 32(4):883-91. PubMed ID: 23877198
    [Abstract] [Full Text] [Related]

  • 25. Neuroprotection by selegiline and other MAO inhibitors.
    Stern G.
    J Neural Transm Suppl; 1998 Oct 30; 52():99-107. PubMed ID: 9564613
    [Abstract] [Full Text] [Related]

  • 26. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM, Mohanakumar KP, Murphy DL, Chiueh CC.
    Ann N Y Acad Sci; 1994 Nov 17; 738():214-21. PubMed ID: 7832430
    [Abstract] [Full Text] [Related]

  • 27. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
    Jenner P.
    Neurology; 2004 Oct 12; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
    [No Abstract] [Full Text] [Related]

  • 28. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N, Damase-Michel C, Senard JM, Rascol O, Montastruc JL.
    Mov Disord; 1997 May 12; 12(3):293-6. PubMed ID: 9159721
    [Abstract] [Full Text] [Related]

  • 29. [Effects of selegiline hydrochloride on intracellular Ca2+ contents in cultured neuronal cells].
    Itoh T, Takahata K, Morimoto K, Iwamoto N, Ohde H.
    No To Shinkei; 1998 Dec 12; 50(12):1093-9. PubMed ID: 9989354
    [Abstract] [Full Text] [Related]

  • 30. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium.
    Koutsilieri E, Chen TS, Rausch WD, Riederer P.
    Eur J Pharmacol; 1996 Jun 13; 306(1-3):181-6. PubMed ID: 8813631
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J.
    Biomed Pharmacother; 1995 Jun 13; 49(4):187-95. PubMed ID: 7669938
    [Abstract] [Full Text] [Related]

  • 33. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion.
    Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han SK, Werner P, Cohen G, Olanow CW.
    J Pharmacol Exp Ther; 1998 Feb 13; 284(2):700-6. PubMed ID: 9454817
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
    Sanz E, Romera M, Bellik L, Marco JI, Unzeta M.
    Med Sci Monit; 2004 Dec 13; 10(12):BR477-84. PubMed ID: 15567979
    [Abstract] [Full Text] [Related]

  • 36. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
    Ebadi M, Sharma SK.
    Antioxid Redox Signal; 2003 Jun 13; 5(3):319-35. PubMed ID: 12880486
    [Abstract] [Full Text] [Related]

  • 37. Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture.
    Yu SJ, Lo ES, Cochran EJ, Lin DH, Faselis CJ, Klawans HL, Carvey PM.
    Exp Neurol; 1994 Mar 13; 126(1):15-24. PubMed ID: 7908885
    [Abstract] [Full Text] [Related]

  • 38. In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson's Disease.
    Choi JG, Park G, Kim HG, Oh DS, Kim H, Oh MS.
    Int J Mol Sci; 2016 Jan 15; 17(1):. PubMed ID: 26784178
    [Abstract] [Full Text] [Related]

  • 39. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 15; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 40. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C, Schumacher HC, Burgut FT.
    Expert Rev Neurother; 2005 Nov 15; 5(6):811-21. PubMed ID: 16274338
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.